Clinical Report: The Impact of SGLT2 Inhibitors on Diabetic Retinopathy Progression

Overview

This study investigates the association between SGLT2 inhibitors and the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. Results indicate that SGLT2 inhibitors are associated with a lower risk of DR progression compared to sulfonylureas.

Background

Diabetic retinopathy is a significant complication of diabetes, affecting approximately 22% of patients. With the increasing prevalence of diabetes, understanding pharmacological strategies to mitigate DR is crucial. SGLT2 inhibitors, originally designed for glycemic control, may have implications for DR progression.

Data Highlights

Key Findings

• SGLT2i+INS was associated with a lower risk of DR progression (HR = 0.40, P = 0.016).
• Reduced cumulative incidence of DR was observed in the SGLT2i+INS group (log-rank P = 0.032).
• The exploratory OCTA-based nomogram showed a C-index of 0.705.
• Mendelian randomization analysis indicated a genetic association between SGLT2 and DR risk (OR = 1.21, P = 0.009).
• Nine metabolites and five plasma proteins showed potential mediating effects.

Clinical Implications

The findings indicate an association between SGLT2 inhibitors and DR progression in insulin-treated patients with type 2 diabetes. Further validation in larger studies is warranted.

Conclusion

SGLT2 inhibitors are associated with a reduced risk of diabetic retinopathy progression compared to sulfonylureas.

Related Resources & Content

1. Frontiers in Endocrinology, 2026 -- Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study
2. conexiant, 2026 -- SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis
3. conexiant, 2026 -- SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk
4. Frontiers in Cardiovascular Medicine, 2026 -- Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations
5. PMC, 2026 -- Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
6. PMC, 2026 -- Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
7. Scientific Reports, 2024 -- Investigating the relationship between blood metabolites and diabetic retinopathy using two-sample mendelian randomization and in vivo validation
8. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 - PMC
9. Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial - PMC
10. Investigating the relationship between blood metabolites and diabetic retinopathy using two-sample mendelian randomization and in vivo validation | Scientific Reports